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a b s t r a c t
Disseminated strongyloidiasis is a disease with high mortality rate, especially in immuno-
compromised individuals. Paralytic ileus and intestinal malabsorption are frequent
symptoms caused by this severe disease. As there are no licensed parenteral anthelmintic
drugs for human use, off-label formulations are often used in the treatment of this disease.
In this case report, the use of subcutaneous ivermectin is described as a successful therapyeywords:
trongyloidiasis
mmunocompromised host
epsis
for this life-threatening infection.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
trongyloidiasis is caused by the nematode Strongyloides ster-
oralis, which infects 50 to 100 million people worldwide.1
his nematode uses the human body as a host and repro-
uces through autoinfection. The two aggressive forms of
he disease are: hyperinfection syndrome or disseminated
trongyloidiasis. In the ﬁrst case, the infection occurs with a
ery heavy worm burden, while in the latter, the larvae pen-
trate the intestine wall and reach the bloodstream, causing
acteremia, meningitis, and septic shock.
The treatment of these severe forms of strongyloidiasis is
till a matter of controversy for immunocompromised and
ritically ill patients who have reduced intestinal absorp-
ion of the oral formulations of antiparasitic drugs. In this
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Este é um artigo Open Access sob a licençacase, the parenteral route is the most feasible and promis-
ing route for treatment since the drugs do not have to be
absorbed by the gastrointestinal tract. In this report, a case
of disseminated strongyloidiasis that was successfully cured
with subcutaneous ivermectin (Ivomec® – Merial, Brazil –
10mg/mL solution) is described. However, it is important to
stress that parenteral treatment with anthelmintics has not
been approved for humans, and its safety is still questionable.
Case presentation
A56-year-oldman fromBrasília (Brazil), whowasunder ambu-Brasília, DF, 70390-903, Brazil.
latory investigation for agranulocytosis and had been using
corticosteroids for eight weeks (prednisone 80mg per day),
came to this hospital with a history of intense asthenia.
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Fig. 1 – Bronchoalveolar lavage sample demonstrating S.
stercoralis larvae. Ziehl-Neelsen stain, x 400.
unsuccessful therapeutic procedures. However, because they
were performed in different situations, they cannot be directly
compared (Fig. 2).At admission, he was afebrile, hypotensive and, accord-
ing to primary examination, presented with leukopenia and
eosinophilia, which were treated with 2g IV cefepime q8h
after collecting blood for cultures.
On the third day after admission, the patient’s respiratory
status deteriorated, and he was transferred to the intensive
care unit. Despite non-invasive ventilation, he required intu-
bation, mechanical ventilation, and vasopressor support by
his ﬁfth day in the hospital. Therefore, antibiotic escalation
was prescribed to broaden the drug spectrum. Additionally,
computed tomography scans of the thorax and abdomen were
performed. The results of the former exam indicated bilateral
areas of pulmonary condensation, and the latter was normal.
Lastly, a pulmonary catheterwasplaced,which showedhemo-
dynamic parameters indicating septic shock.
The patient’s blood tests demonstrated a decreased
hematocrit value, and therefore he underwent an esopha-
gogastroduodenoscopy to rule out bleeding. In this exam,
multiple vegetative lesions were observed, which were associ-
ated with erosions and diffuse enanthema in the duodenum.
On the tenth day of hospitalization, infection with S. stercoralis
was diagnosed based on the duodenal biopsy and the bron-
choalveolar lavage ﬂuid (Fig. 1), which were both performed
simultaneously.
As soon as the nematode was detected, treatment was
immediately initiated with ivermectin via the nasogastric
tube, using 18mg daily, for two days, along with albenda-
zol 400mg q12h. However, on the second day of treatment
it became clear that this treatment was not as effective as
expected and, with the consent of the patient’s family, the
treatment was continued with a veterinary formulation of
subcutaneous ivermectin (Ivomec®; Merial, Brazil – 10mg/mL
solution), and oral use of the drug was discontinued.
This therapy was very successful. On the third day of
anthelmintic treatment, the patient was completely removed
from vasopressor support. On the tenth day, mechanical ven-
tilation was discontinued, and ten days thereafter, the patient
was discharged from the ICU.12;16(5):479–481
Discussion
The patient’s ﬁnal diagnosis was disseminated strongyloidi-
asis with associated septic shock and acute respiratory
distress syndrome. The key indicators leading to this diagno-
sis were the results from the bronchoalveolar lavage and the
esophagogastroduodenoscopy. There have been similar symp-
toms related to this disease based on upper gastrointestinal
endoscopy.2,3 However, these results are not speciﬁc to dis-
seminated strongyloidiasis and are also associated with other
pathological diseases.
Recently, reports4 have indicated that treatment of dis-
seminated strongyloidiasis in immunocompromised patients
with ivermectin is effective, although it is still a matter of
controversy. It has been shown that enteral use of thismedica-
tion could cause pharmacokinetic changes in case of paralytic
ileus,5 jeopardizing its bioavailability and leading to lower con-
centrations of the drug than in its subcutaneous formulation
(0.8 vs. 11.4-17.2 ng/mL).6 Conversely, it has also been argued
that the oral route provides the appropriate plasma and cere-
brospinal ﬂuid concentration of the drug,7 contradicting the
previously mentioned ﬁndings.
Furthermore, the pharmacokinetic properties of iver-
mectin may be modiﬁed in critically ill patients, because the
drug is highly bound to human serum albumin.8 Systemic
inﬂammation causes hypoalbuminemia, and therefore, both
free drug concentration and therapeutic action are elevated.6
Nevertheless, a recent study, which was the ﬁrst to document
total and free levels of subcutaneous ivermectin,3 surprisingly
found less than 1% of free ivermectin located in the plasma.3
A possible explanation for this ﬁnding is the strong binding
between the drug and high alpha-1 acid glycoprotein concen-
tration, which reduces the drug’s distribution to tissues and
contributes to poor therapeutic outcomes.3
Successful7 and unsuccessful3 treatments of disseminated
strongyloidiasis were found. In a case report described by
Rose et al.,8 the patient was treated exclusively with oral iver-
mectin, and this therapy was ineffective; the nematode was
not eliminated, and thepatient died. In other reports, however,
enteral use of this drug successfully eradicated S. stercoralis,
but the patient still died due to toxicity complications6,9 or
due to the severity of the underlying disease.10,11 In the case
described in the present article, favorable outcomes were doc-
umented, as no indication of larva were found in the stool or
bronchoalveolar lavage ﬂuid, and moreover, the patient sur-
vived and was discharged from the intensive care unit and
the hospital.
Thedosage of subcutaneous ivermectinusedwas 15mgper
day for the ﬁrst four days (214g/kg) and then, ﬁve days after
discontinuation of the parenteral ivermectin, an additional
seven-day therapy was initiated (20mg per day; 285g/kg)
because the patient presented with worsening neurological
status and fever. Additionally, there was evidence indicating
that the central nervous system was compromised. A few days
later, the patient’s symptomatologywas diagnosed as herpetic
encephalitis. The following table shows both successful and
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Fig. 2 – Therapeutic regimens for disseminated
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Daily monitoring of the ivermectin concentration in the
erum was essential, as the drug can be toxic to the cen-
ral nervous system. The patient’s persistent coma could have
een confused with symptoms of toxicity even though the
ose (285g/Kg) was eight times lower than what can be toler-
ted byhumans.12 It could also bedue toherpetic encephalitis,
ut because the concentration of drug in the plasma could not
e assessed, this hypothesis could not be conﬁrmed.
With this study, the best treatment for disseminated
trongyloidiasis cannot be deﬁnitely determined. Enteral use
f ivermectin can result in therapeutic failure; in addition,
n some situations, it does achieve adequate plasma levels.
n this patient, parenteral use of this drug was essential for
herapeutic success. Considering that data extrapolated from
nimal experiments are insufﬁcient, it is extremely impor-
ant that reports about the usage of parenteral ivermectin in
umans are discussed, along with its viability and its toxicity,
n order to continue to improve treatment for this devastating
orm of strongyloidiasis.onﬂict of interest
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